ISSN: 2349-5448

Intercontinental Journal of Pharmaceutical Investigations and Research (ICJPIR)

ICJPIR |Vol.10 | Issue 4 | Oct - Dec -2023

www.icjpir.com

DOI : https://doi.org/10.61096/icjpir.v10.iss4.2023.13-16

Review

A Review on Stiff Person Syndrome (SPS)

Elavarasan. N

Assistant Professor, Department of Pharmaceutical Chemistry, S. A. Raja Pharmacy College, Raja Nagar, Vadakangulam, Tirunelveli, Tamil Nadu, India

*AuthorforCorrespondence: Elavarasan. N
Email: elavarasanmpharm@gmail.com

Published on: 16 Nov 2023

Published by:
DrSriram Publications

Abstract

Stiff Person Syndrome (SPS) is a rare, progressive neurological disorder primarily characterized by muscle stiffness, spasms, and functional impairment. Although its precise etiology is unclear, it is often associated with autoimmune responses, frequently observed with elevated anti-glutamic acid decarboxylase (GAD) antibodies. SPS predominantly affects individuals between 30 and 60 years, with a higher incidence in women. Diagnosis is complex, often involving clinical evaluation, blood tests for anti-GAD antibodies, Electromyography (EMG), and MRI scans to exclude other conditions. Treatment approaches are multidimensional, encompassing medication, immunotherapy, physical therapy, and psychotherapy to manage symptoms and improve the patient's quality of life. The prognosis of SPS is variable, and while it may significantly impact the individual's daily living, early diagnosis and appropriate treatment can enhance the patient's life quality. Continuous research and patient support systems are vital for individuals living with SPS. For personalized medical advice, consulting healthcare professionals is recommended.

Keywords: SPS, GAD, GABA.

INTRODUCTION

Stiff Person Syndrome (SPS) is an uncommon and disabling neurological disorder that is often underdiagnosed due to its rarity and the nonspecific nature of its initial symptoms. The syndrome is primarily characterized by increased muscle stiffness, painful spasms, and functional impairment, significantly affecting the affected individuals' quality of life. The pathophysiology of SPS is not entirely understood; however, it is believed to have an autoimmune basis, with many patients presenting elevated levels of anti-glutamic acid decarboxylase (GAD) antibodies. SPS generally manifests between the ages of 30 and 60 and has a higher prevalence in women than in men[(1)]. This introduction aims to provide a foundational understanding of SPS, paving the way for a detailed discussion on its symptoms, diagnosis, treatment options, complications, prognosis, and the ongoing research in the field. Consultation with healthcare professionals is crucial for individuals seeking personalized medical advice and treatment[(2)].

As we delve deeper into the exploration of Stiff Person Syndrome (SPS), it is crucial to acknowledge the multifaceted challenges associated with this syndrome, emphasizing its complexity and the necessity for a

comprehensive approach to its study and management. SPS not only imposes physical distress through muscle stiffness and spasms but also exerts a considerable psychological burden on the affected individuals due to its chronic, progressive nature and the uncertainty surrounding its course[3].

Causes and Pathophysiology

The exact cause of SPS is unknown, but it's thought to be an autoimmune disorder, in which the immune system mistakenly targets and damages neurons that control muscle movement. The presence of autoantibodies against glutamic acid decarboxylase (GAD) is often seen in many patients, suggesting an immune response against this enzyme involved in synthesizing gamma-aminobutyric acid (GABA), a crucial neurotransmitter for inhibiting nerve transmission in the brain (Rakocevic, G., &Floeter, M. K. (2012). Autoimmune stiff person syndrome and related myelopathies: Understanding of electrophysiological and immunological processes. *Muscle & Nerve*, 45(5), 623-634).

- **Autoimmune Response:** Most cases are thought to be autoimmune in nature where the body's immune system mistakenly attacks and damages healthy tissues in the nervous system.
- **Anti-GAD Antibodies:** Many patients have elevated levels of antibodies against glutamic acid decarboxylase (GAD), an enzyme involved in the synthesis of a neurotransmitter called gamma-aminobutyric acid (GABA).

Epidemiology

Stiff Person Syndrome is exceedingly rare, with an estimated prevalence of one to two cases per million. The condition often manifests between ages 30 and 60 but can appear at any age. It also seems to be more common in women than men (Dalakas, M. C. (2019). Stiff person syndrome: Advances in pathogenesis and therapeutic interventions. *Current Treatment Options in Neurology*, 21(3), 12).

Symptom Onset to Diagnosis

The onset of SPS is often insidious, with symptoms gradually escalating in severity and extent. The syndrome typically commences with stiffness in the axial muscles, particularly those of the trunk and lower limbs. As it advances, the stiffness becomes pervasive, affecting a broader range of muscles and precipitating painful spasms that can be debilitating. Individuals with SPS may also exhibit heightened sensitivity to external stimuli, whereby even minor sensory inputs can trigger severe muscle spasms.Patients with SPS often experience a gradual onset of symptoms. The initial signs might be overlooked or mistaken for other conditions, leading to delays in diagnosis and treatment. The muscle stiffness usually starts in the lumbar region, progressing to other parts of the body. Anxiety and depression are common among SPS patients due to the chronic nature of the disorder and its impact on daily living.

- **Muscle Stiffness:** Initial stiffness often occurring in the back and legs.
- **Muscle Spasms:** Painful spasms can be triggered by stimuli like noise, emotional distress, or physical touch.
- **Functional Impairment:** Difficulty moving or walking due to stiffness and spasms.

Clinical Manifestations

Patients with SPS often experience progressive muscle stiffness, which can cause movement difficulties, abnormal posture, and functional impairment. The muscle stiffness is often accompanied by painful spasms triggered by various stimuli. The disorder is often associated with significant psychological distress and can impair the quality of life severely.

Diagnosis

Diagnosing SPS can be challenging due to its rarity and nonspecific initial symptoms. The diagnosis is primarily clinical but supported by the presence of anti-GAD antibodies in the blood. Electromyography (EMG) tests might also reveal the continuous firing of motor units.

- **Clinical Evaluation:** Assessment of symptoms and medical history.
- **Blood Tests:** Checking for the presence of anti-GAD antibodies.
- **Electromyography (EMG):** To evaluate the electrical activity of muscles.
- **MRI Scans:** Although not diagnostic, MRIs can help rule out other conditions.

Differential Diagnosis

Due to its nonspecific symptoms, SPS is often misdiagnosed. It is crucial to rule out other conditions that might mimic SPS, including Parkinson's disease, multiple sclerosis, and tetanus. The presence of anti-GAD antibodies, while not definitive, can aid in the diagnosis, although these antibodies might also be present in other disorders (Levy, L. M., Dalakas, M. C., &Floeter, M. K. (1999). The stiff-person syndrome: an autoimmune

disorder affecting neurotransmission of gamma-aminobutyric acid. *Annals of Internal Medicine*, 131(7), 522-530).

Risk Factors

- **Age:** Although it can occur at any age, it often appears between ages 30 and 60.
- **Gender:** Women are more commonly affected than men.
- **Presence of Other Autoimmune Diseases:** Individuals with other autoimmune conditions may be at a higher risk.

Complications

- **Limited Mobility:** Patients may require walking aids or wheelchairs as the disease progresses.
- **Psychological Distress:** Chronic pain and disability lead to anxiety and depression in many patients.

Treatment

Treatment for SPS is primarily symptomatic and supportive. Medications like diazepam and baclofen are often prescribed to help reduce stiffness and spasms by enhancing GABAergic transmission (Lorish, T. R., Thorsteinsson, G., & Howard, F. M. (1989). Stiff-man syndrome updated. *Mayo Clinic Proceedings*, 64(6), 629-636). Other treatment modalities may include intravenous immunoglobulins (IVIg), plasmapheresis, and physical therapy. Pain and emotional distress should also be addressed, as they can exacerbate the physical symptoms.

- **Medication:** Drugs that enhance GABAergic transmission, like diazepam and baclofen.
- **Immunotherapy:** Treatments like intravenous immunoglobulins (IVIg) or plasmapheresis.
- **Physical Therapy:** To improve mobility and prevent joint contractures.
- **Psychotherapy:** For associated anxiety and depression.

Prognosis

The prognosis of SPS varies from person to person. While the disorder progresses slowly and does not affect life expectancy directly, it significantly impairs the quality of life and can lead to disability. Early diagnosis and appropriate treatment can help manage the symptoms and improve the overall quality of life for individuals with SPS.Prognosis varies significantly from person to person. While the disease progression can often be slow, it can lead to severe disability in some cases. Early diagnosis and appropriate management can improve the quality of life.

Management Advances

In recent years, more targeted immunotherapies have been explored for managing SPS, including rituximab, a medication that depletes B cells, which play a role in the autoimmune process. In addition, researchers are looking at the potential of stem cell transplantation as a therapeutic approach for severe and refractory cases (Dalakas, M. C. (2019). Ibid).

Challenges and Future Directions

Living with SPS poses significant challenges due to the chronic pain, disability, and psychosocial stress associated with the disorder. Patient support groups and advocacy organizations play a vital role in providing resources and support for affected individuals and their families.

Research into the pathophysiology, diagnosis, and treatment of SPS is ongoing, with hopes that a deeper understanding of the disorder's underlying mechanisms will lead to more effective and targeted therapies.

Support

Patient advocacy groups and support networks can provide valuable resources and support for individuals with SPS and their families.

CONCLUSION

Stiff Person Syndrome is a rare, likely autoimmune, neurological disorder that is characterized by muscle stiffness and spasms, resulting in functional impairment and reduced quality of life for affected individuals. A multifaceted approach to management, incorporating pharmacological treatment, physical therapy, and psychological support, is crucial for alleviating symptoms and improving the quality of life for individuals with this disorder.

REFERENCES

1. RakocevicG, FloeterMK. Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. MuscleNerve. 2012;45(5):623-34. doi: 10.1002/mus.23234, PMID 22499087.
2. LorishTR, ThorsteinssonG, HowardFM. Stiff-man syndrome updated. Mayo ClinProc. 1989;64(6):629-36. doi: 10.1016/s0025-6196(12)65339-7, PMID 2664359.
3. Holmøy T, Skorstad G, Røste LS, Scheie D, Alvik K. Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. ClinNeurolNeurosurg. 2009Oct;111(8):708-12. doi: 10.1016/j.clineuro.2009.06.005, PMID 19616370.
4. Witherick J, Highley JR, Hadjivassiliou M. Pathological findings in a case of stiff person syndrome with anti-GAD antibodies. MovDisord. 2011Sep;26(11):2138-9. doi: 10.1002/mds.23784, PMID 21611984.
5. Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology. 2003Jul22;61(2):195-8. doi: 10.1212/01.wnl.0000073143.53337.dd, PMID 12874398.
6. Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. 2019Jan03;19(1):1. (PMCFree article).doi: 10.1186/s12883-018-1232-z, PMID 30606131.
7. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006Sep26;67(6):1068-70. doi: 10.1212/01.wnl.0000237558.83349.d0, PMID 17000981.
8. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol. 2009Mar;11(2):102-10. doi: 10.1007/s11940-009-0013-9, PMID 19210912.
9. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol. 2005Jun;62(6):970-4. doi: 10.1001/archneur.62.6.970, PMID 15956168.
10. Ortiz JF, Ghani MR, Morillo Cox Á, Tambo W, Bashir F, Wirth Met al.Stiff-personsyndrome: A treatmentupdate and newdirections. Cureus. 2020Dec09;12(12):e11995. (PMCFree article).doi: 10.7759/cureus.11995, PMID 33437550.
11. Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff person syndrome with rituximab. J NeurolNeurosurg Psychiatry. 2005Jul;76(7):999-1001. (PMCFree article).doi: 10.1136/jnnp.2004.051144, PMID 15965211.